The latest news in France before distribution of third-generation pneumococcal conjugate vaccines - 18/07/24
, Emmanuelle Varon a, b, e, fHighlights |
• | Serotypes with high invasive disease potential have been added to third-generation pneumococcal conjugate vaccines. |
• | In 2022, in addition to PCV13 coverage for children < 24 months, PCV15 and PCV20 covered 10 % and 36 % of IPDs respectively. |
• | For adults in 2022, in addition to PCV13 coverage, PCVs 15, 20, and 21 covered 3%, 26% and 50% of IPDs respectively. |
• | Evolving PCV recommendations should be considered according to age, vaccine coverage for the booster dose, and underlying health conditions. |
Abstract |
Introduction |
In 2023 in France, 15 valent- pneumococcal conjugate vaccines (PCV15) have been recommended as alternatives to PCV13 for children < 2 years. PCV20 has been recommended for at-risk adults but not yet for infants, while PCV21 targets older adults. We endeavored to estimate the potential benefit of new pneumococcal vaccines in preventing invasive pneumococcal infections by comparing serotype extension to PCV13.
Patients and methods |
The National Reference Centre for Pneumococci distributed S. pneumoniae IPD serotypes from children and adults.
Results |
In 2022, for children under 24 months, PCV15 and PCV20 ensured 10 % and 36 % more coverage against IPD than PCV13. For adults, PCV15, PCV20, and PCV21 covered up to 3 %, 26 %, and 50 % more IPD cases than PCV13.
Conclusion |
The new generation of pneumococcal vaccines could reduce the burden of invasive pneumococcal infections through serotype extension. Additional studies are needed in parallel to optimize their utilization and improve vaccine coverage in France.
Le texte complet de cet article est disponible en PDF.Keywords : Pneumococcal, Vaccination, Children, PCV15, PCV20
Plan
Vol 54 - N° 5
Article 104937- août 2024 Retour au numéro
Article précédent
- Investigation of a cluster of acute epiglottitis in Vendée, western France, October – December 2022
- Gwénola Picard, Pascaline Loury, Ronan Ollivier, Thomas Guimard, Jean-Claude Lacherade, Yves-Marie Vandamme, Farah Boukraa, Lisa A. King
- From imprecise “immune debt” to nuanced “immune shortage”?
- Luwen Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?